Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LX 2020

Drug Profile

LX 2020

Alternative Names: AAV-PKP2; ARVC PKP2 - LEXEO Therapeutics; LX-2020

Latest Information Update: 25 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stelios Therapeutics
  • Developer LEXEO Therapeutics
  • Class Cardiovascular therapies; Gene therapies
  • Mechanism of Action Gene transference; Plakophilin 2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiomyopathies
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cardiomyopathies

Most Recent Events

  • 29 Feb 2024 Phase-I/II clinical trials in Cardiomyopathies (In adults) in USA (IV) (NCT06109181)
  • 19 Dec 2023 Lexeo Therapeutics plans a phase I/II HEROIC-PKP2 trial for Cardiomyopathies (IV) in first half of 2024 (NCT06109181)
  • 18 Dec 2023 LX 2020 receives Fast Track designation from the US FDA for PKP2 arrhythmogenic cardiomyopathy in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top